PT -期刊文章盟Jogdand Prajakta盟——Siddhuraj Premkumar AU -森美智子盟——Sanden卡罗琳AU -琼森,吉米·AU -墙壁,安德鲁·f . AU - Kearley詹妮弗AU - 11,艾莉森·a . AU - Kolbeck罗兰盟——Bjermer列夫盟——纽伯尔德保罗AU - Erjefalt,乔纳斯美国TI -嗜酸性粒细胞,嗜碱性粒细胞,和2型免疫微环境COPD-Affected肺组织援助- 10.1183/13993003.00110 -2019 DP - 2020年1月01 TA -欧洲呼吸杂志PG - 1900110 4099 - //www.qdcxjkg.com/content/early/2020/02/06/13993003.00110 - 2019. -短4100 - //www.qdcxjkg.com/content/early/2020/02/06/13993003.00110 - 2019. -完整的AB -尽管血或痰嗜酸性粒细胞升高出现在许多慢性阻塞性肺病(COPD)患者,浸润肺的嗜酸性粒细胞的解剖分布模式仍存在不确定性。在慢性阻塞性肺病中，嗜碱性粒细胞几乎没有被开发。本研究绘制了组织浸润嗜酸性粒细胞、嗜碱性粒细胞和嗜酸性粒细胞促进肺部感染的免疫机制。从严重程度为I-IV级的COPD患者的主要解剖分区获得外科肺组织和活检;从不吸烟的人/吸烟者作为对照。自动化免疫组织化学和原位杂交鉴定了免疫细胞、2型免疫标记GATA3和eotaxins (CCL11, CCL24)。嗜酸性粒细胞和嗜碱性粒细胞存在于所有受COPD影响的肺解剖分区，在非常严重的COPD中显著增加。嗜酸性粒细胞明显斑片状，局灶性嗜酸性粒细胞丰富的微环境与GATA3+细胞存在空间联系，包括Th2淋巴细胞和2型先天淋巴样细胞。在流感感染小鼠中也发现了类似的局部和IL-33/ st2依赖的嗜酸性粒细胞。 Both mice and patients displayed spatially confined eotaxin signatures with CCL11+ fibroblasts and CCL24+ macrophages.In addition to identifying tissue basophilia as a novel feature of advanced COPD, the identification of spatially confined eosinophil-rich type 2 microenvironments represents a novel type of heterogeneity in the immunopathology of COPD that will likely have implications for personalised treatment.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Jogdand has nothing to disclose.Conflict of interest: Dr. Siddhuraj has nothing to disclose.Conflict of interest: Dr. Mori has nothing to disclose.Conflict of interest: Dr. Sanden has nothing to disclose.Conflict of interest: Dr. Jönsson has nothing to disclose.Conflict of interest: Dr. Walls has nothing to disclose.Conflict of interest: Dr. Kearley reports other from MedImmune LLC, other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Humbles reports other from MedImmune LLC, other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Kolbeck reports other from MedImmune LLC, other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Bjermer has nothing to disclose.Conflict of interest: Dr. Newbold reports other from MedImmune LLC, other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Erjefält reports: JE is founder (and stock owner) of Medetect AB who recieved funding from AstraZeneca for conducting parts of the present study.